viernes, 2 de junio de 2017

New Agenda Release - 8th World Orphan Drug Congress

The World Orphan Drug Congress is back for its 8th annual event in November with a brand new agenda. What new in 2017? Download the agenda to find out.

Here are some key reasons why you must join us 13 - 15 November in Barcelona:


Governed by our Advisory Board, which includes: Yann Le Cam, Dr Ségolène Aymé, Dr Bruno Sepodes (EMA), Alastair Kent (Genetic Alliance UK), Dr Sven Kili (GSK), Professor Michael Linden (Pfizer), Dr Carlo Incerti (Genzyme) and Nicole Boice (Global Genes) these leading experts will ensure the agenda, topics and speakers are relevant and cutting edge, so that your 3 days with us will be the most memorable yet.


Hear from 90+ high-level big pharma, biotech, government, payers, HTA, regulatory and patient organizational speakers. Hear from:
  • Pharma & Biotech - Genzyme, BioMarin, GSK, Roche, Alexion, Prometic, Biogen, Novartis, Takeda, BMS, Pfizer, Bluebird Bio, Abeona Therapeutics, AbbVie, Merck Sharp & Dohme, Selecta Biosciences, ReGenXBio, Horizon Pharma, Yposkesi, Chiesi, GW Pharmaceuticals, Amicus Therapeutics + more!
  • Government, Payers & HTA - G-BA, H-AS, NHS, NICE, Medicines Evaluation Board Netherlands, Norwegian Medicines Agency, TLV Sweden, Catalonia Medicines Agency, Agency for Health Technology Assessment and Tariff System, Poland
  • PAGs & Non-profits - EURORDIS, NORD, Findacure, Fondazione Telethon, Genethon, Duchenne UK, Imagine Foundation, INSERM, Global Genes, FARA¸ Alstrom Syndrome UK
..and many more! We expect over 450 attendees. This is your best chance of the year to meet and network with hundreds of like-minded peers. 


  • Get inspired by plenary speakers from the ORPH-VAL working group and HTA payers to discuss how we can correct the pricing and value discrepancy between countries
  • The EMA recommends shared governance of registries going forward but how will this work? Get a multi-stakeholder discussion from the Medicines Evaluation Board, International Niemann-Pick Disease Alliance and GSK
  • What are the intentions of pharma? Participate in our Executive Industry Discussion with senior representatives from GSK, Roche, Prometic, Novartis and Genzyme, interviewed by INSERM, EURORDIS and Alstrom Syndrome UK – there are so many more amazing sessions, just downloadthe agenda.


I’d like to offer you a personal discount of 40% off the regular ticket price if you book by 9th June 2017. REGISTER NOW

In short, this congress offers your best chance to gain key insights, meet existing and new senior peers, and take part in the forever evolving global orphan drug industry.

Join us for another fantastic event.

Best wishes,

Wing-yun Cheung
Project Director
World Orphan Drug Congress
Tel: +44 20 7092 1172

PS: Register now to save 40% off the regular ticket price by 9th June 2017.

No hay comentarios:

Publicar un comentario